While enteroviruses have been the most commonly identified cause of aseptic meningitis in the United States, the role of the emerging, neurotropic West Nile virus (WNV) is not clear. In summer 2001, an aseptic meningitis epidemic occurring in an area of a WNV epizootic in Baltimore, Maryland, was investigated to determine the relative contributions of WNV and enteroviruses. A total of 113 aseptic meningitis cases with onsets from June 1 to September 30, 2001, were identified at six hospitals. WNV immunoglobulin M tests were negative for 69 patients with available specimens; however, 43 (61%) of 70 patients tested enterovirus-positive by viral culture or polymerase chain reaction. Most (76%) of the serotyped enteroviruses were echoviruses 13 and 18. Enteroviruses, including previously rarely detected echoviruses, likely caused most aseptic meningitis cases in this epidemic. No WNV meningitis cases were identified. Even in areas of WNV epizootics, enteroviruses continue to be important causative agents of aseptic meningitis.
When national surveillance for aseptic meningitis was conducted in the United States, the Centers for Disease Control and Prevention (CDC) received reports of 7,000 to 14,000 cases of aseptic meningitis per year from 1984 to 1994 (1). Enteroviruses are the leading identifiable cause of aseptic meningitis in children and adults, particularly in summer and autumn (2). In smaller proportions, mumps virus (primarily in studies before 1980), herpesviruses, lymphocytic choriomeningitis virus, arboviruses, Leptospira, and many other viral and nonviral agents have been identified in etiologic studies of aseptic meningitis in the United States (3,4). However, the epidemiology of aseptic meningitis is not static and, with the appearance of emerging infectious agents such as West Nile virus (WNV), warrants periodic reevaluation.
WNV infection is usually asymptomatic but may cause a wide range of syndromes including nonspecific febrile illness, meningitis, and encephalitis. In recent WNV epidemics in which neurologic manifestations were prominent (Romania, 1996 ; United States, 1999-2000 [6,7]; and Israel, 2000 ), meningitis was the primary manifestation in 16% to 40% of hospitalized patients with WNV disease. However, because WNV meningitis has nonspecific clinical manifestations and requires laboratory testing for a definitive diagnosis, case ascertainment and testing practices can affect the number of cases diagnosed. Because WNV testing in U.S. surveillance programs has focused on patients with encephalitis of undetermined cause (9), the role of WNV as a cause of aseptic meningitis in the United States is not clear.
A 2001 investigation in Baltimore provided an opportunity to evaluate the role of WNV in the epidemiology of aseptic meningitis and to assess WNV surveillance. From Baltimore City and County, 118 cases of aseptic meningitis with onsets from June 1 to September 30, 2001, were reported to Maryland's Department of Health and Mental Hygiene (DHMH), compared to an average of 39 cases during the same summer season in 1997-2000. Approximately 95% of these 2001 cases were reported without known cause. Simultaneously, an intense WNV epizootic among birds was detected in the Baltimore area (288 WNV-infected dead birds and 14 WNV-infected mosquito pools were collected before September 30, 2001). Early in the summer, nearly 100% of dead crows collected from some sections of Baltimore City tested positive for WNV. When the investigation of aseptic meningitis was initiated in mid-September, one case of human WNV encephalitis had been reported from Baltimore. The investigation's objectives included 1) identification of the predominant cause(s) of the aseptic meningitis epidemic, emphasizing the relative contributions of WNV and enteroviruses and 2) evaluation of hospital-based--WNV surveillance of patients with aseptic meningitis, including strategies used for diagnostic testing.
Discharge Diagnoses Code Review
To confirm an increase in aseptic meningitis cases by a method independent of case reporting to DHMH, a discharge diagnosis code review was conducted at the six investigation hospitals. Included were patients with aseptic meningitis (including International Classification of Diseases [ICD]-9-CM codes 047.0, 047.1, 047.8, 047.9, 049.0, 049.1, 053.0, 054.72, 072.1) who were evaluated from June 1 to September 30, 1998-2001.
The investigation was conducted at six hospitals that collectively reported to DHMH 76% of the 118 aseptic meningitis cases from Baltimore City and County. A case of aseptic meningitis was defined as an illness with onset from June 1 to September 30, 2001; cerebrospinal fluid (CST) cell count of >5 leukocytes per milliliter; negative CSF bacterial cultures; and no physician or laboratory documentation of bacterial, fungal, or parasitic central nervous system (CNS) disease, cerebral hemorrhage, carcinomatous meningitis, or cerebral vasculitis. Neonates who developed CSF abnormalities before first hospital discharge were excluded, as were persons with a physician-documented diagnosis of encephalitis, confusion, or obtundation. A case of enteroviral meningitis was defined as an illness meeting the criteria for aseptic meningitis and, in addition, a positive enterovirus culture of a CSF, rectal swab, or nasopharyngeal specimen, or a positive enterovirus polymerase chain reaction (PCR) test of a CSF specimen. A case of WNV meningitis was defined as an illness meeting the criteria for aseptic meningitis and, in addition, WNV immunoglobulin (Ig) M detected in a CSF specimen by enzyme-linked immunosorbent assay (ELISA), a greater than-four-fold rise of WNV-neutralizing antibodies in acute- and convalescent-phase serum specimens, or WNV nucleic acid detected in a CSF specimen by PCR. The investigation was limited to persons living in Baltimore City or County who were evaluated at one of the six investigation hospitals.
Cases reported to DI IMH as the code "viral meningitis" were reviewed. Depending on the resources of each hospital, additional cases were identified by computerized queries for test results of >5-10 leukocytes per milliliter in CSF, and by review of hospital discharge diagnoses codes. For each case, a standardized form was used to abstract clinical information from the medical record.
Acute-Phase and Convalescent-Phase Specimens and Interviews
Acute-phase (<8 days after illness onset) CSF, serum, rectal swab, and nasopharyngeal specimens were collected if ordered by the patients' physicians. Specimens were stored at hospital, DHMH, or private reference laboratories at temperatures ranging from 4[degrees]C to -70[degrees]C. During home visits to consenting patients >12 years of age who had had aseptic meningitis of unknown cause, convalescent-phase (>7 days after illness onset) blood specimens were collected and a standardized questionnaire was administered to characterize symptoms and duration of illness.
Hospitals performed routine cell counts, chemistries, and bacterial cultures of CSF for patients with sufficient specimen quantity. Some patients' physicians ordered additional tests. These tests commonly included, for CSF specimens, latex agglutination screening tests for bacterial antigens, culture or PCR tests for enteroviruses or herpesviruses, and culture for fungi; for CSF or serum specimens, Borrelia burgdorferi antibody, Venereal Disease Research Laboratory test, and cryptococcal antigen test; and for nasopharyngeal and rectal swab specimens, culture for enteroviruses.
For available specimens from patients with aseptic meningitis of unknown cause, arbovirus serologic testing was performed at DHMH laboratories, and WNV PCR tests were completed at DHMH laboratories or the Division of Vector-Borne Infectious Diseases, CDC. CSF specimens were tested by ELISA for IgM antibodies to WNV and by TaqMan reverse transcriptase (RT-) PCR tests for WNV (10,11). Serum specimens were tested at DHMH laboratories by ELISA for IgM antibodies to WNV, and by immunofluorescence assay (IFA) for IgM and IgG antibodies to La Crosse, St. Louis encephalitis, eastern equine encephalomyelitis, and western equine encephalomyelitis viruses.
Available CSF and rectal swab specimens from patients with aseptic meningitis of unknown cause were tested by enterovirus culture at the Respiratory and Enteric Viruses Branch, CDC. Three cell lines were used at CDC for enterovirus culture: RD (human rhabdomyosarcoma), HELF (human embryonic lung fibroblast), and LLC-MK2 (monkey kidney). Isolates were serotyped by RT-PCR amplification and subsequent sequencing of an approximately 320-nt segment of the VP1 enterovirus gene (12). When available, enteroviruses already isolated by hospital laboratories from CSF, nasopharyngeal, or rectal swab specimens were serotyped by CDC.
Evaluation of Aseptic Meningitis and WNV Surveillance
To evaluate strategies used to diagnose WNV meningitis in Maryland, reporting and testing policies were reviewed. Information was obtained from DHMH case-reports, surveillance plans and summaries, and laboratory tests of investigation patients.
Confirmation of an Epidemic by Discharge Diagnosis Review
Each summer season (June 1-September 30) of 1998-2000, an average of 67 Baltimore residents were evaluated at the six investigation hospitals and assigned an aseptic meningitis ICD-9-CM code; in the 2001 season, 133 persons were evaluated, a 99% increase above the 1998-2000 seasonal average (Figure 1). At one of the investigation hospitals, the specificity of ICD-9-CM codes was assessed. A medical record review showed that 23 (96%) of 24 cases identified by ICD-9-CM codes met the investigation's case definition of aseptic meningitis.
[FIGURE 1 OMITTED]
At the six investigation hospitals, 113 aseptic meningitis patients were identified with illness onsets from June 1 to September 30, 2001. By the week of illness onset, the number of cases peaked in late August and early September (Figure 2). The median patient age was 18 years (range 1 week-74 years of age), and 56% of patients were male. Seventy-eight percent of patients were medically evaluated within the first 3 days after illness onset. Of the 110 patients with available information, the median duration of hospitalization was 2 days (range 0-11 days). No fatalities occurred during hospitalization nor were any subsequently reported to DHMH.
[FIGURE 2 OMITTED]
The median CSF leukocyte count was 135/mL (range 7-1,083/mL). Of the 110 patients with available data, 45 (41%) had >50% polymorphonuclear cells in CSF Leukocyte count, including 9 (43%) of 21 patients who had CSF collected 4-10 days after illness onset. CSF glucose was normal ([greater than or equal to] 40 mg/dL) in 99% of patients (n=110), and CSF protein was elevated (>50 mg/dL) in 52% (n=111: median 53 mg/dL; range 10-215 mg/dL) (Table 1).
On the basis of standardized interviews of 33 patients (median age, 31 years; range 13-55 years of age) at the time convalescent-phase blood specimens were obtained, the most commonly reported acute-phase symptoms were headache (100%), fever (85%), and eye pain or sensitivity to light (85%). Illness was sometimes prolonged by persistent fatigue and headaches. The median duration of illness was 18 days (n=32; range 5-47 days). Twelve of the patients had not fully recovered by the time of interview; for these patients, the duration of illness was defined as (date of interview)--(date of illness onset). Patients [greater than or equal to]18 years of age reported longer duration of symptoms (n=24; median duration 22 days) than patients 13-17 years of age (n=8; median duration 7 days) (p=0.001, Kruskal-Wallis test of significance in Epi-Info 6 software).
WNV Test Results
Of the 69 patients for whom at least one ELISA WNV IgM test was performed on CST or serum, none tested positive. Of these 69, ELISA WNV IgM testing was performed on both acute- and convalescent-phase specimens for 23 patients, on only acute-phase specimens for 36 patients, and on only convalescent-phase specimens for 10 patients. Arboviral IgM IFAs completed on acute- or convalescent-phase serum specimens from 39 patients were all negative. WNV PCR tests completed on acute-phase CSF specimens from 27 patients were also negative. Acute-phase specimens were collected <8 days alter illness onset, and convalescent-phase specimens were collected a median of 40 days after illness onset (range 12-111 days); exact dates were not available for two patients.
Enterovirus Test Results
Of 70 patients who had at least one test (viral culture or PCR test) performed for enteroviruses, 43 (61%) patients were confirmed to have enteroviral meningitis. Among patients who had at least one enterovirus test performed, the percentage enterovirus-positive was highest in infants and children; however, of 30 tested patients [greater than or equal to] 18 years of age, 13 (43%) were enterovirus-positive (Table 2). Of the 34 cases in which enterovirus serotyping was completed, five serotypes were identified. Echovirus 13 (15 cases) and echovirus 18 (11 cases) together accounted for 76% of the serotyped isolates (Table 1).
Two patients were diagnosed with herpes simplex virus meningitis by culture-positive CSF specimens, and one patient was diagnosed with Lyme meningitis on the basis of clinical signs and symptoms of acute facial palsy and meningitis, and positive serum B. burgdorferi antibody by ELISA and Western blot tests.
Sixty-seven (59%) of the 113 patients in the investigation remained undiagnosed; for many, sufficient specimens did not exist for further testing. The median age of these undiagnosed patients was 25 years, and 61% were male. Duration of hospitalization was similar to the cases with known cause. Five of the undiagnosed patients had HIV infection, and another four had a history of prior meningitis. Twenty-seven (40%) of the undiagnosed patients had at least one enterovirus test (culture or PCR) performed. Forty-six (68%) of the undiagnosed patients, including 24 with convalescent-phase specimens collected a median of 44 days after illness onset (exact dates not available for two patients) (range 12-111 days), had at least one WNV IgM ELISA performed. To estimate the number of WNV meningitis cases that could have been missed, we assumed that these 24 patients represented a random sample of the 67 undiagnosed patients; and that WNV infection was ruled out in patients with a negative result from a WNV IgM ELISA performed on a convalescent-phase serum. On the basis of these assumptions, 0% (95% confidence interval 0% to 10%) WNV IgM positivity among the sample suggests that fewer than seven cases of WNV meningitis were missed among the investigation patients.
Evaluation of Aseptic Meningitis and WNV Surveillance
Human WNV surveillance in Maryland focused on patients with two reportable CNS infections, encephalitis or aseptic meningitis, of unknown cause. Of the 113 aseptic meningitis cases identified at the six investigation hospitals, 76 (67%) had been reported to DHMH. Of these 76 aseptic meningitis cases, 71 (93%) were reported without a cause. Because of the urgency to detect WNV epidemics, WNV serologic testing was the first-line test conducted by DHMH laboratories for patients with aseptic CNS infections of unknown cause. WNV testing was first prioritized for patients with encephalitis, and secondarily for hospitalized patients with aseptic meningitis who were [greater than or equal to] 17 years of age (late in the season, this last criteria was expanded to [greater than or equal to] 5 years of age). During 2001, DHMH laboratories conducted WNV testing for 440 patients statewide (including approximately 230 patients reported with aseptic meningitis); 6 patients were diagnosed with WNV disease.
DHMH requested CSF, acute-, and convalescent-phase serum specimens for the diagnosis of WNV infection. However, before the investigation, essentially only acute-phase specimens (CSF more frequently than serum) from Baltimore patients were tested by WNV serologic tests; routine collection of convalescent-phase serum specimens was not feasible.
Enterovirus testing was not a component of DHMH aseptic meningitis surveillance. If enterovirus testing was initiated by the hospital, positive results were often not communicated to DHMH laboratories. Of 69 patients for whom at least one WNV IgM test was performed by DHMH, enteroviral meningitis was subsequently diagnosed in 23 (50% of 46 for whom at least one enterovirus culture or PCR test was performed).
Although enhanced WNV surveillance among persons with aseptic meningitis could have been partially responsible for the tripling of Baltimore case-reports of aseptic meningitis during the summer of 2001, trends in discharge diagnosis codes suggest that a true increase in aseptic meningitis cases occurred. Despite a concurrent, intense WNV epizootic among birds, no evidence existed that WNV substantially contributed to the aseptic meningitis epidemic. By routine surveillance, five WNV encephalitis cases but no WNV meningitis cases were ultimately detected in Baltimore in 2001. However, in this setting, the five recognized WNV encephalitis cases did not appear to represent large numbers of undiagnosed WNV meningitis cases. Surveillance conducted in other states has also suggested that intense WNV epizootic activity does not necessarily correlate with large numbers of human WNV CNS infections (13).
Instead, multiple enterovirus serotypes likely caused most of the Baltimore aseptic meningitis cases. This finding is consistent with population-based studies (14-16) and large outbreak investigations (17,18) of aseptic meningitis occurring during the summer and fall in the United States. However, unlike outbreak investigations of the past few decades, echovirus 13 and echovirus 18 were the most commonly isolated agents in this investigation and might have accounted for the increased number of aseptic meningitis cases in Baltimore. Echovirus 13 was previously rarely detected in the United States. From 1970 to 2000, only 65 of 45,000 enterovirus isolates reported to CDC were echovirus 13 (19). Echovirus 18 had been relatively quiescent for over a decade; from 1988 to 2000, only 200 isolates were reported to CDC (20). In a study conducted from 1986 to 1990 in Baltimore hospitals among infants <2 years of age who were hospitalized with aseptic meningitis, only one case of echovirus 13 and two cases of echovirus 18 (among 167 serotyped enterovirus isolates) meningitis were identified (14).
In 2001, the previously rarely detected echoviruses 13 and 18 were the two enteroviruses most commonly reported to CDC (20). Multiple states reported echovirus 13 in association with aseptic meningitis outbreaks, and Tennessee reported an aseptic meningitis outbreak attributed to both echovirus 13 and 18 (19). Where previously rarely detected, echovirus 13 was isolated in association with aseptic meningitis outbreaks in Australia during 2001 (21) and in the United Kingdom (22) and Germany (23) during 2000. Surveillance data have previously demonstrated that in one or two seasons a usually quiescent serotype may cause an outburst of clinical disease super-imposed on background, area-endemic enteroviruses (24). The worldwide spread of epidemics of clinical enteroviral disease has been documented with other serotypes, including echovirus 9 and enterovirus 70 (25).
Limitations of this study should be acknowledged. Physicians may have diagnosed more aseptic meningitis in response to WNV publicity; however, physicians more likely recognized that the risk and discomfort of a lumbar puncture required to diagnose meningitis outweighed the public health interest in identifying an untreatable condition, WNV meningitis. Regarding the investigation, only aseptic meningitis cases that could be rapidly identified at the six Baltimore hospitals were included. Not all patients underwent the same tests in the same laboratories, and the quality of enterovirus testing differed because of variable conditions of specimens. Additional results of other tests performed at reference laboratories might have become available only after the investigation ended. As a result, although any positive WNV test result would likely have been reported, the percentage of enterovirus test-positive cases could be inaccurate. Finally, similar to previous studies of the epidemiology of aseptic meningitis (2), 59% of cases remain undiagnosed; another, untested agent may have caused the increased number of aseptic meningitis cases in Baltimore.
The consistent predominance of enteroviruses among the known causes of aseptic meningitis in children and adults versus the relative infrequency of WNV meningitis (even during an intense WNV epizootic) warrants reconsideration of WNV surveillance testing strategies. Most cases of aseptic meningitis were reported to DHMH without a known cause. For these patients, WNV testing was the first priority to enable early detection of WNV epidemics that would warrant additional vector control interventions. By contrast, enterovirus testing was not a component of surveillance among patients with aseptic meningitis. Although no WNV meningitis was identified, >30% of the patients who underwent WNV testing were later determined to have had enteroviral meningitis. Many patients with aseptic meningitis were tested for an apparently rare virus, WNV before being tested for the common agents, enteroviruses. During nonepidemic years, WNV IgM ELISA may be low yield when performed as a first-line test for aseptic meningitis. By contrast, enterovirus testing likely can identify the cause of a large fraction of aseptic meningitis cases.
They complexities and resource requirements of WNV serologic testing suggest that other testing strategies need to be developed. During 2001, DHMH laboratories conducted WNV testing for 440 patients statewide, often performing multiple tests for each patient; 6 patients were diagnosed with WNV disease. WNV ELISAs require at least 2-3 days to complete. PCR tests for WNV in CSF specimens are more rapid but have poor sensitivity (26). Because patients often seek medical care early after illness onset when WNV antibodies might not be detectable, serologic tests of specimens collected at the time of first symptoms may also have poor sensitivity. Serologic testing of convalescent-phase serum specimens may be the most sensitive method to detect WNV infection. Yet, collecting convalescent-phase specimens can be logistically difficult and, as in Baltimore's WNV surveillance program, may not be routinely feasible. When collected through primary care physicians, billing issues can be problematic, and each home visit for collection of blood specimens may require several hours of staff time.
An improved laboratory-based surveillance strategy might include a two-stage testing algorithm at hospital or public health laboratories to evaluate patients with aseptic meningitis. The goals would be 1) to judiciously use specimens of limited quantity (especially CSF) to rapidly identify common or treatable causes of aseptic meningitis and 2) to improve the yield of the more complex testing required to diagnose arboviral disease.
As a first stage of testing, multiplex PCR tests have been used to detect enteroviruses, herpes simplex 1 and 2, and varicella zoster (27,28). Several studies indicate that PCR tests for enteroviruses (29) and herpes simplex virus (30) are highly specific, can be completed more rapidly (<6 hours required), require less quantity of CSF, and potentially are more sensitive than traditional cell culture. Using PCR tests to identify enterovirus infections in patients with aseptic meningitis can reduce unnecessary ancillary tests and antibiotic or antiviral therapy and allows shortened hospitalizations (31). In addition, treatment for enteroviral infection may become available in the near future (32).
If no diagnosis is made after completion of screening tests for common or treatable agents and evidence of regional WNV or other arbovirus activity exists, a second stage of testing might include arbovirus IgM ELISA of acute- and convalescent-phase specimens. To rule out WNV disease, WNV IgM and WNV IgG ELISAs may need to be conducted approximately 8-45 days after illness onset (WNV IgG ELISAs may be complicated by cross-reactions that can only be differentiated by logistically difficult plaque reduction neutralization tests) (10). The importance of the timing of specimen collection should be clearly communicated to healthcare providers.
The epidemiology of aseptic meningitis and other CNS infections is not fixed and may vary by location; in the same location, the epidemiology may vary by different seasons. For example, while relatively quiescent in most years, WNV has the potential to cause large epidemics in humans. Because WNV disease does not have unique clinical manifestations, adequate laboratory testing is the only way to identify human WNV epidemics. Refinement of laboratory testing strategies for WNV surveillance may help build broader public health laboratory capacity for the diagnosis of arboviral and other CNS infections.
The authors thank the many persons at hospitals, laboratories, Baltimore City and County health departments. Maryland's Department of Health and Mental Hygiene, and Centers for Disease Control and Prevention who contributed time and effort to this investigation, especially infection control practitioners: Kathleen Arias, Ruth Bertuzzi, Colleen Clay, Jeanine Brown, Diane Lagasse, Polly Ristaino, Donna Feldman, Phyllis Tyler, Joanne Venturella, and Matthew Wallace; Joseph Scaletta for providing Maryland's zoonotic WNV surveillance data; and Brad Biggerstaff for statistical advice.
(1.) Centers for Disease Control and Prevention. Summary of notifiable diseases, United States 1994. MMWR Morb Mortal Wkly Rep 1995;43:1-80.
(2.) Rotbart HA. Viral meningitis and the aseptic meningitis syndrome. In: Scheld, WM, Whitley RJ, Durack DT, editors. Infections of the central nervous system. 2nd ed. Philadelphia: Lippincott-Raven; 1997. p. 23-46.
(3.) Deibel R, Srihongse S, Woodall JP. Arboviruses in New York State: an attempt to determine the role of arboviruses in patients with viral encephalitis and meningitis. Am J Trop Med Hyg 1979;28:577-82.
(4.) Tunkel AR, Scheld WM. Acute meningitis. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 5th ed. New York: Churchill Livingstone; 2000. p. 959-97.
(5.) Tsai TF, Popovici F, Cernescu C, Campbell GL, Nedelcu NI, for the Investigative Team. West Nile encephalitis epidemic in southeastern Romania. Lancet 1998;352:767-71.
(6.) Nash D, Mostashari F, Fine A, Miller J, O'Leary D, Murray K, et al. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med 2001;344:1807-14.
(7.) Marfin AA, Petersen LR, Eidson M, Miller J, Hadler J, Farello C, et al. Widespread West Nile virus activity, eastern United States, 2000. Emerg Infect Dis 2001;7:730-5.
(8.) Chowers MY, Lang R, Nassar F, Ben-David D, Giladi M, Rubinshtein E, et al. Clinical characteristics of the West Nile fever outbreak, Israel, 2000. Emerg Infect Dis 2001;7:675-8.
(9.) Centers for Disease Control and Prevention. Epidemic/epizootic West Nile virus in the United States: revised guidelines for surveillance, prevention, and control. Washington: Department of Health and Human Services; 2001. Available from URL: http://www.cdc.gov/ncidod/dvbid/westnile/resources /wnv-guide-lines-apr-2001.pdf
(10.) Martin DA, Muth DA, Brown T, Johnson AJ, Karabatsos N, Roehrig JT. Standardization of immunoglobulin M capture enzyme-linked immunosorbent assays for routine diagnosis of arboviral infections. J Clin Microbiol 2000;38:1823-6.
(11.) Lanciotti RS, Kerst AJ, Nasci RS, Godsey MS, Mitchell CJ, Savage HM, et al. Rapid detection of West Nile virus from human clinical specimens, field-collected mosquitoes, and avian samples by a TaqMan reverse transcriptase-PCR assay. J Clin Microbiol 2000;38:4066-71.
(12.) Oberste MS, Maher K, Flemister MR, Marchetti G, Kilpatrick DR, Pallansch MA. Comparison of classic and molecular approaches for the identification of untypeable enteroviruses. J Clin Microbiol 2000;38:1170-4.
(13.) Hadler J, Nelson R, McCarthy T, Andreadis T, Lis MJ, French R, et al. West Nile virus surveillance in Connecticut in 2000: an intense epizootic without high risk for severe human disease. Emerg Infect Dis 2001;7:636-42.
(14.) Berlin LE, Rorabaugh ML, Heldrich F, Roberts K, Doran T, Modlin JF. Aseptic meningitis in infants <2 years of age: diagnosis and etiology. J Infect Dis 1993;168:888-92.
(15.) Beghi E, Nicolosi A, Kurland LT, Mulder DW, Hauser WA, Shuster L. Encephalitis and aseptic meningitis, Olmsted County, Minnesota, 1950-1981: I. Epidemiology. Ann Neurol 1984;16:283-94.
(16.) Lepow ML, Carver DH, Wright HT, Woods WA, Robbins FC. A clinical, epidemiologic and laboratory investigation of aseptic meningitis during the four-year period, 1955-1958: I. Observations concerning etiology and epidemiology. N Engl J Med 1962;266:1181-7.
(17.) Sawyer MH, Holland D, Aintablian N, Connor JD, Keyser EF, Waecker NJ Jr. Diagnosis of enteroviral central nervous system infection by polymerase chain reaction during a large community outbreak. Pediatr Infect Dis J 1994;13:177-82.
(18.) Lennette EH, Magoffin RL, Knouf EG. Viral central nervous system disease: an etiologic study conducted at the Los Angeles County General Hospital. JAMA 1962;179:687-95.
(19.) Centers for Disease Control and Prevention. Echovirus type 13--United States, 2001. MMWR Morb Mortal Wkly Rep 2001;50:777-80.
(20.) Khetsuriani N, Oberste S, Mullins J, Nix W, LaMonte A, Dunn J, et al. Changes in circulating nonpolio enterovirus serotypes in the United States. Clinical Virology Symposium; 2002, Apr 28-May 1; Clearwater Beach, Florida.
(21.) McMinn P. Meningitis, echoviruses 13 & 30-Australia (western). ProMed. September 17, 2001. Accessed at: http://www.promedmail.org, archive number: 20010917.2247.
(22.) Communicable Disease Surveillance Centre. Viral meningitis associated with increase in echovirus type 13. Commun Dis Rep CDR Wkly 2000;10:277, 280.
(23.) Twisselmann B. Cluster of cases of viral meningitis caused by echovirus type 13 in Germany. Eurosurveillance Weekly [serial online] 2000 Oct 5 [cited 2002 Jun 13];40. Available from: URL: http://www.eurosurv.org/2000/001005.htm
(24.) Strikas RA, Anderson LJ, Parker RA. Temporal and geographic patterns of isolates of nonpolio enterovuus in the United States, 1970-1983. J Infect Dis 1986;153:346-51.
(25.) Melnick J. Polioviruses and other enteroviruses. In: Evans AS, Kaslow RA, editors. Viral infections of humans: epidemiology and control. 4th ed. New York: Plenum Medical Book Co.; 1997. p. 583-663.
(26.) Lanciotti RS, Kerst AJ. Nucleic acid sequence-based amplification assays for rapid detection of West Nile and St. Louis encephalitis viruses. J Clin Microbiol 2001;39:4506-13.
(27.) Read SJ, Mitchell JL, Fink CG. LightCycler multiplex PCR for the laboratory diagnosis of common viral infections of the central nervous system. J Clin Microbiol 2001;39:3056-9.
(28.) Chesky M, Scalco R, Failace L, Read S, Jobim LF. Polymerase chain reaction for the laboratory diagnosis of aseptic meningitis and encephalitis. Arq Neuropsiquiatr 2000;58:836-42.
(29.) Rotbart HA, Ahmed A, Hickey S, Dagan R, McCracken GH Jr, Whitley RJ, et al. Diagnosis of enterovirus infection by polymerase chain reaction of multiple specimen types. Pediatr Infect Dis J 1997;16:409-11.
(30.) Lakeman FD, Whitley RJ. Diagnosis of herpes simplex encephalitis: application of polymerase chain reaction to cerebrospinal fluid from brain-biopsied patients and correlation with disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis 1995;171:857-63.
(31.) Ramers C, Billman G, Hartin M, Ho S, Sawyer MH. Impact of a diagnostic cerebrospinal fluid enterovirus polymerase chain reaction test on patient management. JAMA 2000;283:2680-5.
(32.) Rotbart HA. Treatment of picornavirus infections. Antiviral Res 2002;53:83-98.
Dr. Julian is currently in training in infectious diseases at the Penn State Milton S. Hershey Medical Center. The original work for this study was conducted while Dr. Julian was an Epidemic Intelligence Service officer in the Arbovirus Diseases Branch, Centers for Disease Control and Prevention. She participated in surveillance for West Nile virus and for adverse events potentially related to yellow fever vaccine.
Address for correspondence: Kathleen G. Julian; Penn State Milton S. Hershey Medical Center; Division of Infectious Diseases, BMR Bldg Rm C6833, Hershey Medical Center, 500 University Dr., Hershey, PA 17033; fax: 717-531-4633; email:firstname.lastname@example.org
Kathleen G. Julian, * James A. Mullin, ([dagger]) Annette Olin, ([double dagger]) Heather Peters, ([section]) W. Allan Nix, ([dagger]) M. Steven Oberste, ([dagger]) Judith C. Lovchik, ([paragraph]) Amy Bergmann, ([section]) Ross J. Brechner, ([section]) Robert A. Myers, ([section]) Anthony A. Marfin, * and Grant L. Campbell *
* Centers for Disease Control and Prevention, Fort Collins, Colorado, USA; ([dagger]) Centers for Disease Control and Prevention, Atlanta, Georgia, USA; ([double dagger]) St. Matthew's School of Medicine, Grand Caymans, British West Indies; ([section]) Maryland Department of Health and Mental Hygiene, Baltimore, Maryland, USA; and ([paragraph]) University of Maryland Medical Center, Baltimore, Maryland, USA
COPYRIGHT 2003 U.S. National Center for Infectious Diseases
COPYRIGHT 2003 Gale Group